Mannoside Glycolipid Conjugates Display Antiviral Activity Against Ebola Virus.
Fiche publication
Date publication
novembre 2018
Journal
The Journal of infectious diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MUELLER Christopher
Tous les auteurs :
Reynard O, Schaeffer E, Volchkova VA, Cimarelli A, Mueller CG, Volchkov VE
Lien Pubmed
Résumé
The West African outbreak of Ebola virus (EBOV) infection during 2013-2016 highlighted the need for development of field-applicable therapeutic drugs for this infection. Here we report that mannoside glycolipid conjugates (MGCs) consisting of a trimannose head and a lipophilic chain assembled by a linker inhibit EBOV infection not only of human monocyte-derived dendritic cells and macrophages, but also of a number of susceptible cells. Analysis of the mode of action leads us to conclude that MGCs act directly on cells, notably by preventing virus endocytosis.
Mots clés
Animals, Antiviral Agents, pharmacology, Chlorocebus aethiops, Ebolavirus, drug effects, Glycolipids, pharmacology, Humans, Mannosides, therapeutic use, Vero Cells, Virus Internalization, drug effects
Référence
J Infect Dis. 2018 11 22;218(suppl_5):S666-S671